

83-6-02 85



RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/723,713

DATE: 03/06/2002
TIME: 10:07:15

Input Set : N:\Crf3\RULE60\09723713.txt
Output Set: N:\CRF3\03062002\I723713.raw

3 <110> APPLICANT: Schenk, Dale B.
4 Neuralab Limited
6 <120> TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
8 <130> FILE REFERENCE: 15270J-004740US
10 <140> CURRENT APPLICATION NUMBER: 09/723,713
11 <141> CURRENT FILING DATE: 2000-11-27
13 <150> PRIOR APPLICATION NUMBER: 09/322,289
14 <151> PRIOR FILING DATE: 1999-05-28
16 <160> NUMBER OF SEQ ID NOS: 5
18 <170> SOFTWARE: PatentIn Ver. 2.1
20 <210> SEQ ID NO: 1
21 <211> LENGTH: 42
22 <212> TYPE: PRT
23 <213> ORGANISM: Homo sapiens
25 <220> FEATURE:
26 <223> OTHER INFORMATION: human Abeta42 beta-amyloid peptide
28 <400> SEQUENCE: 1
29 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
30 1 5 10 15
32 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
33 20 25 30
35 Gly Leu Met Val Gly Gly Val Val Ile Ala
36 35 40
39 <210> SEQ ID NO: 2
40 <211> LENGTH: 13
41 <212> TYPE: PRT
42 <213> ORGANISM: Artificial Sequence
44 <220> FEATURE:
45 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta1-12
46 peptide with carboxyl terminal Cys residue
47 inserted
49 <400> SEQUENCE: 2
50 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val Cys
51 1 5 10
54 <210> SEQ ID NO: 3
55 <211> LENGTH: 6
56 <212> TYPE: PRT
57 <213> ORGANISM: Artificial Sequence
59 <220> FEATURE:
60 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta1-5
61 peptide with carboxyl terminal Cys residue
62 inserted
64 <400> SEQUENCE: 3

ENTERED

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/723,713

DATE: 03/06/2002

TIME: 10:07:15

Input Set : N:\Crf3\RULE60\09723713.txt
Output Set: N:\CRF3\03062002\I723713.raw

65 Asp Ala Glu Phe Arg Cys
66 1 5
69 <210> SEQ ID NO: 4
70 <211> LENGTH: 12
71 <212> TYPE: PRT
72 <213> ORGANISM: Artificial Sequence
74 <220> FEATURE:
75 <223> OTHER INFORMATION: Description of Artificial Sequence: Abeta33-42
76 peptide with carboxyl terminal Cys residue
77 inserted
79 <220> FEATURE:
80 <221> NAME/KEY: MOD_RES
81 <222> LOCATION: (2)
82 <223> OTHER INFORMATION: Xaa = amino heptanoic acid
84 <400> SEQUENCE: 4
W--> 85 Cys Xaa Gly Leu Met Val Gly Gly Val Val Ile Ala
86 1 5 10
89 <210> SEQ ID NO: 5
90 <211> LENGTH: 19
91 <212> TYPE: PRT
92 <213> ORGANISM: Artificial Sequence
94 <220> FEATURE:
95 <223> OTHER INFORMATION: Description of Artificial Sequence: Abeta13-28
96 peptide with carboxyl terminal Cys residue
97 inserted and two added Gly residues
99 <220> FEATURE:
100 <221> NAME/KEY: MOD_RES
101 <222> LOCATION: (1)
102 <223> OTHER INFORMATION: Xaa = acetyl histidine
104 <400> SEQUENCE: 5
W--> 105 Xaa His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
106 1 5 10 15
108 Gly Gly Cys

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/723,713

DATE: 03/06/2002

TIME: 10:07:16

Input Set : N:\Crf3\RULE60\09723713.txt
Output Set: N:\CRF3\03062002\I723713.raw

L:85 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4

L:105 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5